Susquehanna Fundamental Investments, LLC Jounce Therapeutics, Inc. Transaction History

Susquehanna Fundamental Investments, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.73 - $4.92 $97,455 - $175,634	-35,698 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$6.01 - $8.54 $57,095 - $81,129	9,500 Added 36.26%	35,698 $242,000
Q4 2021 Feb 14, 2022	SELL	$7.11 - $9.64 $24,209 - $32,824	-3,405 Reduced 11.5%	26,198 $219,000
Q3 2021 Nov 15, 2021	SELL	$5.04 - $8.73 $21,122 - $36,587	-4,191 Reduced 12.4%	29,603 $220,000
Q2 2021 Aug 11, 2021	BUY	$6.58 - $10.66 $222,364 - $360,244	33,794 New	33,794 $230,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.